What Current Evidence and Clinical Trials Tell Us The key published evidence is a 2023 Phase 2 RCT (Jastreboff et al.) showing substantial weight loss and predominantly mild-to-moderate GI side effects
Most practitioners finish school and still dont have a clue how to turn a profit
Additionally, we believe the results of LIBERATE-1 may provide clinical validation of our NanoPortal drug delivery technology to support a broader application of the technology in the treatment of chronic diseases. LIBERATE-1 will be a randomized investigation of the safety, tolerability and pharmacokinetic profile of the exenatide NanoPortal implant in obese or overweight patients
Tailored Nutrition & Supplement Guidance: Go beyond generic advicedeliver customized solutions that maximize client results
Common contexts include: Chronic inflammation 12 Chronic fatigue syndrome 13,14 Fibromyalgia 14 Asthma 15 Cardiovascular conditions 16 Autoimmune activity 17 Neurodegenerative presentations 9 Liver-related detoxification pathways 18 Diabetes associated neuropathy 19 Mental health presentations, including depression, anxiety, bipolar disorder, and schizophrenia, 20 Skin concerns, including hyperpigmentation 6 Glutathione IV, Troches, Nasal Spray, and Injections Glutathione can be prepared in several delivery forms commonly used in clinical settings, including: 250 mg troche used sublingually 100 mg/mL nasal spray, typically one spray per nostril once or twice daily Injectable solutions for IM, SC, or IV use, with dosing generally ranging from 100 to 500 mg depending on route and frequency Note: Injectable administration may cause noticeable stinging due to the molecules properties
When calorie intake drops, as it reliably does on tirzepatide, the body mobilizes stored triglycerides from adipose tissue
